-
"Guilin Chinese Medicine Resources Code" is issued to promote the sustainable development of Chinese medicine industry
Time of Update: 2021-08-28
Jiang Pinghua said that Guilin is currently actively exploring “to create a suitable technology promotion center for traditional Chinese medicine with strong comprehensive service capabilities, outstanding Chinese medicine characteristics, and obvious specialty advantages, and to explore standard and standardized Chinese medicine diagnosis and treatment models”.
-
Xinjiang releases an announcement on the communication and communication procedures for the change management category of drugs after the listing
Time of Update: 2021-08-28
On August 13, the Drug Administration of Xinjiang Uygur Autonomous Region issued an announcement on the “Working Procedures for Communication and Exchange of Post-marketing Drugs in Xinjiang Uygur Aut
-
JiMu Biological Suprachoroidal Cavity Injection Therapy Obtains Exclusive Rights and Interests in Ten ASEAN Countries and India
Time of Update: 2021-08-28
On August 15th, JiMu Biotech announced that it has reached a license supplementary agreement with its partner Clearside Biomedical, Inc. (hereinafter referred to as “Clearside”), regarding its core p
-
Allogene's multiple myeloma therapy ALLO-715 won the FDA rare disease drug title
Time of Update: 2021-08-28
ALLO-715 is a CAR-T therapy targeting B cell maturation antigen (BCMA) and a potential new therapy for the treatment of multiple myeloma and other BCMA-positive malignancies .
-
New medicine for atopic dermatitis!
Time of Update: 2021-08-28
AbbVie recently announced the evaluation of the oral JAK1 inhibitor Rinvoq (upadacitinib, upatinib) and the subcutaneous injection preparation Dupixent (Chinese trade name: dabital, generic name: dupilumab) The results of the head-to-head Phase 3b Heads Up study (NCT03738397) in adult patients with moderate to severe atopic dermatitis (AD) have been published in the international medical journal "JAMA Dermatology" .
-
Ophthalmology medication!
Time of Update: 2021-08-28
Vascular endothelial growth factor (VEGF) is an important regulator of neovascularization (called angiogenesis) and plays a key role in the progression of retinopathy of prematurity; if blood vessels fail to develop normally, blood vessels may stretch the retina and cause the macula Traction, retinal detachment, or other structural abnormalities that can cause vision loss or even blindness .
-
The licensed pharmacist has started to evaluate the deputy chief pharmacist
Time of Update: 2021-08-28
As early as 2019, the "Notice on Doing a Good Job in the Evaluation of Professional Titles in Our Province's Pharmaceutical Industry in 2019" issued by the Guangdong Provincial Food and Drug Administration talked about the effective connection with the national licensed pharmacist examination professional qualification system .
-
Is the K drug with 30 indications expected to conquer pancreatic cancer?
Time of Update: 2021-08-27
Clinical research success rate of different solid tumors (Source: NextPharma database)Therefore, it is not difficult to understand that surgery, radiotherapy, and chemotherapy are still the main treatments for pancreatic cancer .
-
Sichuan Provincial Food and Drug Administration announced that 3 batches of drugs did not meet the requirements
Time of Update: 2021-08-27
Medical Network, August 18, on August 16, the Sichuan Provincial Food and Drug Administration issued a notice on its official website, informing that Huixing Pharmaceutical’s Omeprazole Enteric-coated Capsules, Xinrentai Pharmaceutical Longan Meat, and Xinli Traditional Chinese Medicine Decoction Company Poria skin 3 The batch of drugs does not meet the regulations .
-
The first provincial-level cross-regional procurement alliance for Chinese patent medicine is coming!
Time of Update: 2021-08-27
Chinese medicine into the Central Purchasing large variety of sales further pressure In recent years, affected by the adjustment of medical insurance policies and the gradual refinement of the rational drug use policy in hospitals , the overall growth rate of the Chinese patent medicine market has continued to slow down .
-
One billion retail oral antithrombotic drugs are "emergency"!
Time of Update: 2021-08-27
A few days ago, the official website of the State Food and Drug Administration showed that Shaanxi Buchang High-tech Pharmaceuticals was approved for imitating Rivaroxaban tablets for production in Ca
-
Chuangsheng Group completed the first patient administration of Claudin 18.2 monoclonal antibody TST001 Phase IIa trial
Time of Update: 2021-08-27
Recently, Chuangsheng Group announced that the first patient in the phase IIa clinical trial of TST001 has successfully completed the administration on August 17 .
-
China's vaccine sales in the first half of the year are expected to hit the world's first
Time of Update: 2021-08-27
Looking back at the company's announcements in the past six months, it can be found that the main reason for the sharp increase in the profit of China Biopharmaceuticals is mainly from the revenue of Kexing Zhongwei vaccine .
-
$2.4 billion anti-inflammatory and anti-rheumatic drug!
Time of Update: 2021-08-27
A few days ago, the official website of CDE showed that Sichuan Kelun Pharmaceutical Research Institute|Sichuan Kelun Pharmaceutical was accepted for imitation of tofacitib citrate sustained-release tablets of 3 types of applications .
-
Directors of Yunnan Baiyao Wang Rong and Na Pengjie resign
Time of Update: 2021-08-27
Wang Rong proposed to resign from the company’s vice chairman, director and all other positions due to personal health reasons (because Mr.
Na Pengjie is due to his work , Proposed to resign as a director of the company and all other positions.
-
The Phase I clinical study of Sansheng Guojian anti-IL-1β monoclonal antibody completed the first subject enrollment
Time of Update: 2021-08-27
As pleiotropic cytokines with multiple local and systemic effects, IL-1 family members are central mediators of innate immunity and inflammatory response, and play a key role in the biology of multiple inflammatory diseases .
-
More than 1,600 public hospitals in my country's Internet hospitals become the main force for construction
Time of Update: 2021-08-27
According to statistics from the National Health Commission, as of June 2021, there are more than 1,600 Internet hospitals in China, initially forming an online and offline integrated medical service model .
-
Lung cancer vaccine has poor efficacy!
Time of Update: 2021-08-27
The company said that despite CureVac's decision to terminate the partnership with Boehringer Ingelheim on the project, the two companies will continue to look for other ways to cooperate and apply CureVac's RNA technology to other potential therapeutic purposes in other ways .
-
BeiGene PD-1 new indication for the first-line treatment of nasopharyngeal carcinoma is reported to be launched
Time of Update: 2021-08-27
On May 21 this year, BeiGene announced that, as recommended by the Independent Data Testing Committee, a tislelizumab combined with chemotherapy versus placebo combined with chemotherapy is used for the first-line treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) The Phase 3 RATIONALE309 clinical trial of the therapy reached the primary endpoint in the interim analysis .
-
"Innovative Drug One Brother" Outbreak This month, 10 Class 1 New Drugs Intensively Strike
Time of Update: 2021-08-27
Sales of terminal anti-tumor drugs in physical pharmacies in cities in China (unit: ten thousand yuan) Source: Mi Nei. com, China's urban physical pharmacy terminal competition pattern For newly approved innovative drugs, retail pharmacies are the main battlefield for sales .
